Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 307
Filtrar
1.
Biochem Soc Trans ; 49(6): 2483-2493, 2021 12 17.
Artigo em Inglês | MEDLINE | ID: mdl-34747992

RESUMO

Transcription is regulated and mediated by multiprotein complexes in a chromatin context. Transcription causes changes in DNA topology which is modulated by DNA topoisomerases, enzymes that catalyse changes in DNA topology via transient breaking and re-joining of one or both strands of the phosphodiester backbone. Mammals have six DNA topoisomerases, this review focuses on one, DNA topoisomerase II beta (TOP2B). In the absence of TOP2B transcription of many developmentally regulated genes is altered. Long genes seem particularly susceptible to the lack of TOP2B. Biochemical studies of the role of TOP2B in transcription regulated by ligands such as nuclear hormones, growth factors and insulin has revealed PARP1 associated with TOP2B and also PRKDC, XRCC5 and XRCC6. Analysis of publicly available databases of protein interactions confirms these interactions and illustrates interactions with other key transcriptional regulators including TRIM28. TOP2B has been shown to interact with proteins involved in chromosome organisation including CTCF and RAD21. Comparison of publicly available Chip-seq datasets reveals the location at which these proteins interact with genes. The availability of resources such as large datasets of protein-protein interactions, e.g. BioGrid and IntAct and protein-DNA interactions such as Chip-seq in GEO enables scientists to extend models and propose new hypotheses.


Assuntos
DNA Topoisomerases Tipo II/fisiologia , Proteínas de Ligação a Poli-ADP-Ribose/fisiologia , Transcrição Gênica/fisiologia , Animais , DNA Topoisomerases Tipo II/genética , DNA Topoisomerases Tipo II/metabolismo , Humanos , Proteínas de Ligação a Poli-ADP-Ribose/genética , Proteínas de Ligação a Poli-ADP-Ribose/metabolismo , Ligação Proteica
2.
Clin Cancer Res ; 27(20): 5669-5680, 2021 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-34433651

RESUMO

PURPOSE: The epigenetic mechanisms involved in transcriptional regulation leading to malignant phenotype in gliomas remains poorly understood. Topoisomerase IIB (TOP2B), an enzyme that decoils and releases torsional forces in DNA, is overexpressed in a subset of gliomas. Therefore, we investigated its role in epigenetic regulation in these tumors. EXPERIMENTAL DESIGN: To investigate the role of TOP2B in epigenetic regulation in gliomas, we performed paired chromatin immunoprecipitation sequencing for TOP2B and RNA-sequencing analysis of glioma cell lines with and without TOP2B inhibition and in human glioma specimens. These experiments were complemented with assay for transposase-accessible chromatin using sequencing, gene silencing, and mouse xenograft experiments to investigate the function of TOP2B and its role in glioma phenotypes. RESULTS: We discovered that TOP2B modulates transcription of multiple oncogenes in human gliomas. TOP2B regulated transcription only at sites where it was enzymatically active, but not at all native binding sites. In particular, TOP2B activity localized in enhancers, promoters, and introns of PDGFRA and MYC, facilitating their expression. TOP2B levels and genomic localization was associated with PDGFRA and MYC expression across glioma specimens, which was not seen in nontumoral human brain tissue. In vivo, TOP2B knockdown of human glioma intracranial implants prolonged survival and downregulated PDGFRA. CONCLUSIONS: Our results indicate that TOP2B activity exerts a pleiotropic role in transcriptional regulation of oncogenes in a subset of gliomas promoting a proliferative phenotype.


Assuntos
Neoplasias Encefálicas/genética , DNA Topoisomerases Tipo II/fisiologia , Epigênese Genética/fisiologia , Glioma/genética , Íntrons/fisiologia , Oncogenes/fisiologia , Proteínas de Ligação a Poli-ADP-Ribose/fisiologia , Regiões Promotoras Genéticas/fisiologia , Animais , Neoplasias Encefálicas/enzimologia , Regulação Neoplásica da Expressão Gênica , Glioma/enzimologia , Humanos , Camundongos
3.
Biochemistry ; 60(21): 1630-1641, 2021 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-34008964

RESUMO

The extensive length, compaction, and interwound nature of DNA, together with its controlled and restricted movement in eukaryotic cells, create a number of topological issues that profoundly affect all of the functions of the genetic material. Topoisomerases are essential enzymes that modulate the topological structure of the double helix, including the regulation of DNA under- and overwinding and the removal of tangles and knots from the genome. Type II topoisomerases alter DNA topology by generating a transient double-stranded break in one DNA segment and allowing another segment to pass through the DNA gate. These enzymes are involved in a number of critical nuclear processes in eukaryotic cells, such as DNA replication, transcription, and recombination, and are required for proper chromosome structure and segregation. However, because type II topoisomerases generate double-stranded breaks in the genetic material, they also are intrinsically dangerous enzymes that have the capacity to fragment the genome. As a result of this dualistic nature, type II topoisomerases are the targets for a number of widely prescribed anticancer drugs. This article will describe the structure and catalytic mechanism of eukaryotic type II topoisomerases and will go on to discuss the actions of topoisomerase II poisons, which are compounds that stabilize DNA breaks generated by the type II enzyme and convert these essential enzymes into "molecular scissors." Topoisomerase II poisons represent a broad range of structural classes and include anticancer drugs, dietary components, and environmental chemicals.


Assuntos
DNA Topoisomerases Tipo II/metabolismo , DNA Topoisomerases Tipo II/fisiologia , DNA Topoisomerases Tipo II/ultraestrutura , Antineoplásicos/química , DNA/química , Dano ao DNA/genética , Dano ao DNA/fisiologia , Eucariotos/genética , Eucariotos/metabolismo , Genoma/genética , Humanos , Inibidores da Topoisomerase II/química , Inibidores da Topoisomerase II/farmacologia , Translocação Genética/genética
4.
Cell Cycle ; 20(4): 345-352, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33459116

RESUMO

DNA Topoisomerase II (TopoII) uses ATP hydrolysis to decatenate chromosomes so that sister chromatids can faithfully segregate in mitosis. When the TopoII enzyme cycle stalls due to failed ATP hydrolysis, the onset of anaphase is delayed, presumably to allow extra time for decatenation to be completed. Recent evidence revealed that, unlike the spindle assembly checkpoint, this TopoII checkpoint response requires Aurora B and Haspin kinases and is triggered by SUMOylation of the C-terminal domain of TopoII.


Assuntos
Aurora Quinase B/fisiologia , DNA Topoisomerases Tipo II/fisiologia , Peptídeos e Proteínas de Sinalização Intracelular/fisiologia , Pontos de Checagem da Fase M do Ciclo Celular/fisiologia , Metáfase/fisiologia , Proteínas Serina-Treonina Quinases/fisiologia , Animais , Proteínas de Ciclo Celular/fisiologia , Genes cdc/fisiologia , Humanos , Mitose/fisiologia
5.
Genes (Basel) ; 10(11)2019 10 30.
Artigo em Inglês | MEDLINE | ID: mdl-31671531

RESUMO

Type II topoisomerases are ubiquitous enzymes in all branches of life that can alter DNA superhelicity and unlink double-stranded DNA segments during processes such as replication and transcription. In cells, type II topoisomerases are particularly useful for their ability to disentangle newly-replicated sister chromosomes. Growing lines of evidence indicate that eukaryotic topoisomerase II (topo II) activity is monitored and regulated throughout the cell cycle. Here, we discuss the various roles of topo II throughout the cell cycle, as well as mechanisms that have been found to govern and/or respond to topo II function and dysfunction. Knowledge of how topo II activity is controlled during cell cycle progression is important for understanding how its misregulation can contribute to genetic instability and how modulatory pathways may be exploited to advance chemotherapeutic development.


Assuntos
Ciclo Celular/fisiologia , DNA Topoisomerases Tipo II/metabolismo , DNA Topoisomerases Tipo II/fisiologia , Animais , Ciclo Celular/genética , Pontos de Checagem do Ciclo Celular , Divisão Celular , Cromossomos/metabolismo , DNA/metabolismo , Replicação do DNA/genética , Replicação do DNA/fisiologia , DNA Topoisomerases Tipo II/genética , Células Eucarióticas/metabolismo , Humanos , Mitose/fisiologia , Inibidores da Topoisomerase II
6.
Nucleic Acids Res ; 47(13): 6946-6955, 2019 07 26.
Artigo em Inglês | MEDLINE | ID: mdl-31165864

RESUMO

Recent studies have revealed that the DNA cross-inversion mechanism of topoisomerase II (topo II) not only removes DNA supercoils and DNA replication intertwines, but also produces small amounts of DNA knots within the clusters of nucleosomes that conform to eukaryotic chromatin. Here, we examine how transcriptional supercoiling of intracellular DNA affects the occurrence of these knots. We show that although (-) supercoiling does not change the basal DNA knotting probability, (+) supercoiling of DNA generated in front of the transcribing complexes increases DNA knot formation over 25-fold. The increase of topo II-mediated DNA knotting occurs both upon accumulation of (+) supercoiling in topoisomerase-deficient cells and during normal transcriptional supercoiling of DNA in TOP1 TOP2 cells. We also show that the high knotting probability (Pkn ≥ 0.5) of (+) supercoiled DNA reflects a 5-fold volume compaction of the nucleosomal fibers in vivo. Our findings indicate that topo II-mediated DNA knotting could be inherent to transcriptional supercoiling of DNA and other chromatin condensation processes and establish, therefore, a new crucial role of topoisomerase II in resetting the knotting-unknotting homeostasis of DNA during chromatin dynamics.


Assuntos
DNA Topoisomerases Tipo II/fisiologia , DNA Super-Helicoidal/metabolismo , Conformação de Ácido Nucleico , Proteínas de Saccharomyces cerevisiae/fisiologia , Transcrição Gênica/genética , Cromatina/ultraestrutura , DNA Topoisomerases Tipo I/metabolismo , DNA Fúngico/metabolismo , Humanos , Nucleossomos/metabolismo , Saccharomyces cerevisiae/metabolismo
7.
Planta ; 249(4): 1119-1132, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30552583

RESUMO

MAIN CONCLUSION: Cotton GaTOP6B is involved in cellular endoreduplication and a positive response to drought stress via promoting plant leaf and root growth. Drought is deemed as one of adverse conditions that could cause substantial reductions in crop yields worldwide. Since cotton exhibits a moderate-tolerant phenotype under water-deficit conditions, the plant could therefore be used to characterize potential new genes regulating drought tolerance in crop plants. In this work, GaTOP6B, encoding DNA topoisomerase VI subunit B, was identified in Asian cotton (Gossypium arboreum). Virus-induced gene silencing (VIGS) and overexpression (OE) were used to investigate the biological function of GaTOP6B in G. arboreum and Arabidopsis thaliana under drought stress. The GaTOP6B-silencing plants showed a reduced ploidy level, and displayed a compromised tolerance phenotype including lowered relative water content (RWC), decreased proline content and antioxidative enzyme activity, and an increased malondialdehyde (MDA) content under drought stress. GaTOP6B-overexpressing Arabidopsis lines, however, had increased ploidy levels, and were more tolerant to drought treatment, associated with improved RWC maintenance, higher proline accumulation, and reduced stomatal aperture under drought stress. Transcriptome analysis showed that genes involved in the processes like cell cycle, transcription and signal transduction, were substantially up-regulated in GaTOP6B-overexpressing Arabidopsis, promoting plant growth and development. More specifically, under drought stress, the genes involved in the biosynthesis of secondary metabolites such as phenylpropanoid, starch and sucrose were selectively enhanced to improve tolerance in plants. Taken together, the results demonstrated that GaTOP6B could coordinately regulate plant leaf and root growth via cellular endoreduplication, and positively respond to drought stress. Thus, GaTOP6B could be a competent candidate gene for improvement of drought tolerance in crop species.


Assuntos
Endorreduplicação/genética , Genes de Plantas/fisiologia , Gossypium/genética , Arabidopsis , Proteínas Arqueais/genética , Proteínas Arqueais/fisiologia , Clorofila/metabolismo , DNA Topoisomerases Tipo II/genética , DNA Topoisomerases Tipo II/fisiologia , Desidratação , Citometria de Fluxo , Genes de Plantas/genética , Gossypium/crescimento & desenvolvimento , Gossypium/metabolismo , Gossypium/fisiologia , Malondialdeído/metabolismo , Folhas de Planta/crescimento & desenvolvimento , Proteínas de Plantas/genética , Proteínas de Plantas/fisiologia , Raízes de Plantas/crescimento & desenvolvimento , Transpiração Vegetal , Plantas Geneticamente Modificadas , Prolina/metabolismo , Reação em Cadeia da Polimerase em Tempo Real
8.
Cell ; 175(2): 583-597.e23, 2018 10 04.
Artigo em Inglês | MEDLINE | ID: mdl-30220456

RESUMO

When DNA is unwound during replication, it becomes overtwisted and forms positive supercoils in front of the translocating DNA polymerase. Unless removed or dissipated, this superhelical tension can impede replication elongation. Topoisomerases, including gyrase and topoisomerase IV in bacteria, are required to relax positive supercoils ahead of DNA polymerase but may not be sufficient for replication. Here, we find that GapR, a chromosome structuring protein in Caulobacter crescentus, is required to complete DNA replication. GapR associates in vivo with positively supercoiled chromosomal DNA, and our biochemical and structural studies demonstrate that GapR forms a dimer-of-dimers that fully encircles overtwisted DNA. Further, we show that GapR stimulates gyrase and topo IV to relax positive supercoils, thereby enabling DNA replication. Analogous chromosome structuring proteins that locate to the overtwisted DNA in front of replication forks may be present in other organisms, similarly helping to recruit and stimulate topoisomerases during DNA replication.


Assuntos
Cromossomos Bacterianos/fisiologia , DNA Bacteriano/química , DNA Super-Helicoidal/metabolismo , Proteínas de Bactérias/metabolismo , Caulobacter crescentus/metabolismo , Caulobacter crescentus/fisiologia , Estruturas Cromossômicas/fisiologia , Cromossomos Bacterianos/metabolismo , DNA/fisiologia , Replicação do DNA/fisiologia , DNA Topoisomerases Tipo I/metabolismo , DNA Topoisomerases Tipo II/metabolismo , DNA Topoisomerases Tipo II/fisiologia , DNA Bacteriano/fisiologia , Escherichia coli/metabolismo , Regulação Bacteriana da Expressão Gênica/genética , Cinética
9.
Biochim Biophys Acta Mol Basis Dis ; 1864(1): 197-207, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29045811

RESUMO

It has been reported that Topoisomerase II alpha (TOP2A) could induce tumor development and progression in many cancer types. Herein, through analysis of different independent cohorts, we found TOP2A was up-regulated in pancreatic cancer as compared with non-tumor tissues. Moreover, the up-regulation of TOP2A was significantly correlated with tumor metastasis and shorter survival in patients with pancreatic cancer. Knockdown of TOP2A in pancreatic cancer cell lines inhibited cell proliferation and migration. Furthermore, bioinformatics analysis revealed TOP2A activatesß-catenin pathway in pancreatic cancer. Mechanistically, we demonstrated TOP2A acts as a co-activator ofß-catenin and activates EMT process. Further investigation showed TOP2A was a direct target of mir-139, which was validated by dual-luciferase reporter gene assay. The effects of mir-139 on pancreatic cancer were also mechanistically, functionally and clinically investigated. Taken together, our research identified a novel miR-139\TOP2A\ß-catenin axis driving the malignant progression of pancreatic cancer.


Assuntos
DNA Topoisomerases Tipo II/fisiologia , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patologia , Proteínas de Ligação a Poli-ADP-Ribose/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Linhagem Celular Tumoral , Proliferação de Células/genética , Transição Epitelial-Mesenquimal/genética , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Pessoa de Meia-Idade , Via de Sinalização Wnt , beta Catenina/metabolismo
10.
J Environ Pathol Toxicol Oncol ; 36(3): 207-216, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29283334

RESUMO

The aim of this study was to investigate topoisomerase II alpha (TOP2α) overexpression and its association with clinicopathological features and prognosis in gastric cancer (GC) patients. All selected GC patients at Affiliated Hospital of Qinghai University and Cancer Hospital, Chinese Academy of Medical Sciences, between December 2009 and December 2011, had formalin-fixed and paraffin-embedded tumor tissues. The patients received a telephone follow-up or in-/outpatient review, and their clinicopathological features and prognoses were analyzed. Also, the relationship between TOP2α expression and postoperative chemotherapy in GC patients was estimated. The results of the study showed that TOP2α overexpression correlated with location of tumor, depth of invasion, and pTNM stage. Moreover, it was associated with lower 5-year overall survival (OS) in noncardia GC patients younger than 60 years, with multivariate analysis demonstrating that it was an independent prognostic factor for these patients. Univariate analysis and multivariate analysis showed that TOP2α overexpression was associated with worse 5-year OS in noncardia GC patients ≤ 60 years receiving postoperative chemotherapy. TOP2α overexpression exhibited associations with location of tumor, depth of invasion, pTNM stage, and postoperative chemotherapy, making it a potential target for early diagnosis of GC patients. In addition, TOP2α overexpression was shown to be a predictor of 5-year OS in both noncardia GC patients ≤ 60 years and noncardia GC patients ≤ 60 years and receiving postoperative chemotherapy.


Assuntos
DNA Topoisomerases Tipo II/fisiologia , Neoplasias Gástricas/mortalidade , Adulto , Idoso , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Neoplasias Gástricas/enzimologia , Neoplasias Gástricas/patologia , Neoplasias Gástricas/terapia
11.
Med Sci (Paris) ; 33(5): 512-518, 2017 May.
Artigo em Francês | MEDLINE | ID: mdl-28612727

RESUMO

During sexual reproduction haploid gametes are generated out of diploid mother cells. This ploidy reduction is accomplished during meiosis and, in most species, relies on the occurrence of homologous recombination that is triggered by the induction of a large number of DNA double strand breaks (DSBs). The mechanism by which such DSBs are generated without provoking massive DNA breakdown in gamete mother cells is still poorly understood. However, the recent characterisation, in plants and in mammals, of a new component of the meiotic DSB forming machinery, defining a meiotic-specific TOPOVIB-Like protein family, has established a clear connection between the meiotic DSB activity and topoisomerases, enzymes that modify the DNA topology by introducing transient DSBs.


Assuntos
Proteínas Arqueais/fisiologia , Quebras de DNA de Cadeia Dupla , DNA Topoisomerases Tipo II/fisiologia , Endodesoxirribonucleases/fisiologia , Recombinação Genética/genética , Animais , Proteínas Arqueais/genética , DNA Topoisomerases Tipo II/genética , Endodesoxirribonucleases/genética , Humanos , Mamíferos , Plantas , Subunidades Proteicas/genética , Subunidades Proteicas/fisiologia , Saccharomyces cerevisiae/genética
12.
Nucleic Acids Res ; 45(10): 5995-6010, 2017 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-28472494

RESUMO

Topoisomerase (topo) IIα and IIß maintain genome stability and are targets for anti-tumor drugs. In this study, we demonstrate that the decatenation checkpoint is regulated, not only by topo IIα, as previously reported, but also by topo IIß. The decatenation checkpoint is most efficient when both isoforms are present. Regulation of this checkpoint and sensitivity to topo II-targeted drugs is influenced by the C-terminal domain (CTD) of the topo II isoforms and by a conserved non-catalytic tyrosine, Y640 in topo IIα and Y656 in topo IIß. Deletion of most of the CTD of topo IIα, while preserving the nuclear localization signal (NLS), enhances the decatenation checkpoint and sensitivity to topo II-targeted drugs. In contrast, deletion of most of the CTD of topo IIß, while preserving the NLS, and mutation of Y640 in topo IIα and Y656 in topo IIß inhibits these activities. Structural studies suggest that the differential impact of the CTD on topo IIα and topo IIß function may be due to differences in CTD charge distribution and differential alignment of the CTD with reference to transport DNA. Together these results suggest that topo IIα and topo IIß cooperate to maintain genome stability, which may be distinctly modulated by their CTDs.


Assuntos
Antígenos de Neoplasias/química , Pontos de Checagem do Ciclo Celular/fisiologia , Instabilidade Cromossômica/fisiologia , DNA Topoisomerases Tipo II/química , Proteínas de Ligação a DNA/química , Sequência de Aminoácidos , Animais , Antígenos de Neoplasias/efeitos dos fármacos , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/fisiologia , Linhagem Celular , Dano ao DNA , DNA Topoisomerases Tipo II/efeitos dos fármacos , DNA Topoisomerases Tipo II/genética , DNA Topoisomerases Tipo II/fisiologia , DNA Complementar/genética , Proteínas de Ligação a DNA/efeitos dos fármacos , Proteínas de Ligação a DNA/genética , Proteínas de Ligação a DNA/fisiologia , Resistencia a Medicamentos Antineoplásicos , Fibroblastos , Células HL-60 , Humanos , Camundongos , Mutagênese Sítio-Dirigida , Domínios Proteicos , Proteínas Recombinantes/metabolismo , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos , Relação Estrutura-Atividade , Inibidores da Topoisomerase II/farmacologia
13.
Int J Cancer ; 140(4): 864-876, 2017 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-27813122

RESUMO

Quercetin (Que) is an abundant flavonoid in the human diet and high-concentration food supplement with reported pro- and anti-carcinogenic activities. Topoisomerase II (TopoII) inhibition and subsequent DNA damage induction by Que was implicated in the mixed lineage leukemia gene (MLL) rearrangements that can induce infant and adult leukemias. This notion raised concerns regarding possible genotoxicities of Que in hematopoietic stem and progenitor cells (HSPCs). However, molecular targets mediating Que effects on DNA repair relevant to MLL translocations have not been defined. In this study we describe novel and potentially genotoxic Que activities in suppressing non-homologous end joining and homologous recombination pathways downstream of MLL cleavage. Using pharmacological dissection of DNA-PK, ATM and PI3K signalling we defined PI3K inhibition by Que with a concomitant decrease in the abundance of key DNA repair genes to be responsible for DNA repair inhibition. Evidence for the downstream TopoII-independent mutagenic potential of Que was obtained by documenting further increased frequencies of MLL rearrangements in human HSPCs concomitantly treated with Etoposide and Que versus single treatments. Importantly, by engaging a tissue engineered placental barrier, we have established the extent of Que transplacental transfer and hence provided the evidence for Que reaching fetal HSPCs. Thus, Que exhibits genotoxic effects in human HSPCs via different mechanisms when applied continuously and at high concentrations. In light of the demonstrated Que transfer to the fetal compartment our findings are key to understanding the mechanisms underlying infant leukemia and provide molecular markers for the development of safety values.


Assuntos
Transformação Celular Neoplásica/efeitos dos fármacos , Dano ao DNA , Reparo do DNA/efeitos dos fármacos , DNA Topoisomerases Tipo II/fisiologia , Células-Tronco Hematopoéticas/efeitos dos fármacos , Histona-Lisina N-Metiltransferase/genética , Leucemia/induzido quimicamente , Proteína de Leucina Linfoide-Mieloide/genética , Inibidores de Fosfoinositídeo-3 Quinase , Quercetina/toxicidade , Transdução de Sinais/efeitos dos fármacos , Inibidores da Topoisomerase II/toxicidade , Adulto , Ácido Ascórbico/farmacologia , Técnicas de Cultura de Células , Células Cultivadas , Ensaio de Unidades Formadoras de Colônias , Relação Dose-Resposta a Droga , Etoposídeo/farmacologia , Feminino , Genisteína/farmacologia , Histonas/análise , Humanos , Lactente , Leucemia/genética , Troca Materno-Fetal , Fosfatidilinositol 3-Quinases/fisiologia , Gravidez
14.
Zhong Nan Da Xue Xue Bao Yi Xue Ban ; 41(11): 1143-1147, 2016 Nov 28.
Artigo em Chinês | MEDLINE | ID: mdl-27932758

RESUMO

OBJECTIVE: To detect the expressions of human epidermal growth factor receptor 2 (HER2) and Topo IIα in breast cancer, and to analyze the clinical significance of neoadjuvant chemotherapy for the anthracycline-based drugs.
 Methods: The HER2 and Topo IIα gene and protein expressions in cancer tissues from 189 patients with breast cancer were detected by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). And the objective response rate (ORR) and pathological complete rate (pCR) were analyzed.
 Results: The HER2 protein expression in 46 patients (24.3%) and Topo IIα protein expression in 55 patients (29.1%) was 3+ by IHC or they were 49 (25.9%) and 94 (49.0%) by FISH, respectively. The ORR and pCR in HER2 negative or positive patients were 47.4% and 20.3% or 32.7% and 16.3%, respectively, with significant differences (All P<0.05). The ORR and pCR in Topo IIα positive or negative patients were 69.1% and 36.0% or 28.4% and 2.2%, respectively, with significant differences (All P<0.05).
 Conclusion: FISH and IHC were consistent in the determination of HER2 expression whereas they were inconsistent in the determination of Topo IIα expression. The amplification of Topo IIα can effectively improve the effect of the adjuvant treatment effect of the anthracyclines.


Assuntos
Antraciclinas/farmacologia , Neoplasias da Mama/química , Neoplasias da Mama/genética , Neoplasias da Mama/terapia , DNA Topoisomerases Tipo II/fisiologia , Receptor ErbB-2/fisiologia , Antraciclinas/uso terapêutico , Antibióticos Antineoplásicos , Feminino , Humanos , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Terapia Neoadjuvante , Resultado do Tratamento
15.
Genes Cells ; 21(10): 1113-1124, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27610954

RESUMO

Although the condensin complexes and topoisomerase IIα (TopoIIα) are the central players in mitotic chromosome formation, they are insufficient for its completion, and additional factors involved in the process have been extensively sought. In this study, we examined the possibility that Ki67, a perichromosomal protein widely used as a cell proliferation marker, is one such factor. Using a combination of auxin-inducible degron and CRISPR-Cas9-based gene editing technologies, we generated a human HCT116 cell line in which Ki67 is rapidly depleted in a few hours. The removal of Ki67 before mitotic entry did not impact the early mitotic chromosome assembly observed in prophase but subsequently resulted in the formation of misshapen mitotic chromosomes. When Ki67 was removed after mitotic entry, preassembled rod-shaped mitotic chromosomes became disorganized. In addition, we show that Ki67 and TopoIIα are reciprocally coimmunoprecipitated from mitotic cell extracts. These observations indicate that Ki67 aids the finalization of mitotic chromosome formation and helps maintain rod-shaped chromosome architecture, likely in collaboration with TopoIIα. Together, these findings represent a new model in which mitotic chromosome architecture is supported both internally and externally.


Assuntos
Cromossomos Humanos/fisiologia , Antígeno Ki-67/fisiologia , Mitose/fisiologia , Antígenos de Neoplasias/fisiologia , DNA Topoisomerases Tipo II/fisiologia , Proteínas de Ligação a DNA/fisiologia , Células HCT116 , Células HeLa , Humanos , Antígeno Ki-67/genética , Modelos Biológicos
16.
Plant Cell Rep ; 35(6): 1297-307, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26956135

RESUMO

KEY MESSAGE: PAT1H1, one of the homologues of Topoisomerase II-associated protein, is involved in the maintenance of root stem cell niche through the interaction with NINJA. The root stem cell niche, which possesses four mitotically inactive quiescent cells (QC) and the surrounding mitotically active stem cells, is critical for root development in Arabidopsis thaliana. However, the molecular regulation of the maintenance of root stem cell niche identity is still not fully understood. Here we show that one of the homologues of Topoisomerase II-associated protein, here named as PAT1H1, could regulate root stem cell niche identity. The pat1h1 mutant showed higher frequency of QC cell division and root distal stem cell (DSC) differentiation. With a high expression in roots, PAT1H1 was found to interact with the jasmonic acid (JA) signalling negative regulator Novel Interactor of JAZ (NINJA) and thus regulate root DSC niche identity. Consistent with the active QC cell division, which rarely occurs in wild-type controls, the pat1h1 mutant displayed higher expression of CYCB1 in the root stem cell niche. Together our data reveals that PAT1H1 maintains root stem cell niche stability through the interaction with NINJA and the regulation of cell division.


Assuntos
Proteínas de Arabidopsis/fisiologia , DNA Topoisomerases Tipo II/fisiologia , Raízes de Plantas/fisiologia , Nicho de Células-Tronco/fisiologia , Divisão Celular/fisiologia , Raízes de Plantas/citologia , Reação em Cadeia da Polimerase , Proteínas Repressoras/fisiologia , Técnicas do Sistema de Duplo-Híbrido
18.
Sci Rep ; 5: 11916, 2015 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-26132639

RESUMO

Chromosome higher order structure has been an enigma for over a century. The most important structural finding has been the presence of a chromosome scaffold composed of non-histone proteins; so-called scaffold proteins. However, the organization and function of the scaffold are still controversial. Here, we use three dimensional-structured illumination microscopy (3D-SIM) and focused ion beam/scanning electron microscopy (FIB/SEM) to reveal the axial distributions of scaffold proteins in metaphase chromosomes comprising two strands. We also find that scaffold protein can adaptably recover its original localization after chromosome reversion in the presence of cations. This reversion to the original morphology underscores the role of the scaffold for intrinsic structural integrity of chromosomes. We therefore propose a new structural model of the chromosome scaffold that includes twisted double strands, consistent with the physical properties of chromosomal bending flexibility and rigidity. Our model provides new insights into chromosome higher order structure.


Assuntos
Proteínas Cromossômicas não Histona/ultraestrutura , Cromossomos Humanos/ultraestrutura , Adenosina Trifosfatases/fisiologia , Adenosina Trifosfatases/ultraestrutura , Antígenos de Neoplasias/fisiologia , Antígenos de Neoplasias/ultraestrutura , Proteínas Cromossômicas não Histona/fisiologia , Cromossomos Humanos/fisiologia , DNA Topoisomerases Tipo II/fisiologia , DNA Topoisomerases Tipo II/ultraestrutura , Proteínas de Ligação a DNA/fisiologia , Proteínas de Ligação a DNA/ultraestrutura , Células HeLa , Humanos , Imageamento Tridimensional , Cinesinas/fisiologia , Cinesinas/ultraestrutura , Metáfase , Complexos Multiproteicos/fisiologia , Complexos Multiproteicos/ultraestrutura
19.
Oncotarget ; 6(11): 8960-73, 2015 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-25840421

RESUMO

Both microtubule and topoisomerase II (Top2) are important anticancer targets and their respective inhibitors are widely used in combination for cancer therapy. However, some combinations could be mutually antagonistic and drug resistance further limits their therapeutic efficacy. Here we report YCH337, a novel α-carboline derivative that targets both microtubule and Top2, eliciting tumor proliferation and growth inhibition and overcoming drug resistance. YCH337 inhibited microtubule polymerization by binding to the colchicine site and subsequently led to mitotic arrest. It also suppressed Top2 and caused DNA double-strand breaks. It disrupted microtubule more potently than Top2. YCH337 induced reversible mitotic arrest at low concentrations but persistent DNA damage. YCH337 caused intrinsic and extrinsic apoptosis and decreased MCL-1, cIAP1 and XIAP proteins. In this aspect, YCH337 behaved differently from the combination of vincristine and etoposide. YCH337 inhibited proliferation of tumor cells with an averaged IC50 of 0.3 µM. It significantly suppressed the growth of HT-29 xenografts in nude mice too. Importantly, YCH337 nearly equally killed different-mechanism-mediated resistant tumor cells and corresponding parent cells. Together with the novelty of its chemical structure, YCH337 could serve as a promising lead for drug development and a prototype for a dual microtubule/Top2 targeting strategy for cancer therapy.


Assuntos
Carbolinas/uso terapêutico , Quebras de DNA de Cadeia Dupla/efeitos dos fármacos , DNA de Neoplasias/efeitos dos fármacos , Proteínas de Neoplasias/antagonistas & inibidores , Inibidores da Topoisomerase II/uso terapêutico , Moduladores de Tubulina/uso terapêutico , Animais , Apoptose/efeitos dos fármacos , Sítios de Ligação/efeitos dos fármacos , Ligação Competitiva , Carbolinas/farmacologia , Linhagem Celular Tumoral , Colchicina/metabolismo , Neoplasias do Colo/tratamento farmacológico , DNA Topoisomerases Tipo II/fisiologia , DNA Super-Helicoidal/efeitos dos fármacos , Interações Medicamentosas , Ensaios de Seleção de Medicamentos Antitumorais , Etoposídeo/farmacologia , Humanos , Concentração Inibidora 50 , Metáfase/efeitos dos fármacos , Camundongos , Camundongos Nus , Microtúbulos/efeitos dos fármacos , Microtúbulos/metabolismo , Estrutura Molecular , Proteínas de Neoplasias/biossíntese , Proteínas de Neoplasias/fisiologia , Paclitaxel/farmacologia , Inibidores da Topoisomerase II/síntese química , Inibidores da Topoisomerase II/farmacologia , Tubulina (Proteína)/metabolismo , Moduladores de Tubulina/síntese química , Moduladores de Tubulina/farmacologia , Vincristina/farmacologia
20.
Oncogene ; 34(31): 4019-31, 2015 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-25328138

RESUMO

Genome instability is a hallmark of cancer cells. Chromosome instability (CIN), which is often mutually exclusive from hypermutation genotypes, represents a distinct subtype of genome instability. Hypermutations in cancer cells are due to defects in DNA repair genes, but the cause of CIN is still elusive. However, because of the extensive chromosomal abnormalities associated with CIN, its cause is likely a defect in a network of genes that regulate mitotic checkpoints and chromosomal organization and segregation. Emerging evidence has shown that the chromosomal decatenation checkpoint, which is critical for chromatin untangling and packing during genetic material duplication, is defective in cancer cells with CIN. The decatenation checkpoint is known to be regulated by a family of enzymes called topoisomerases. Among them, the gene encoding topoisomerase IIα (TOP2A) is commonly altered at both gene copy number and gene expression level in cancer cells. Thus, abnormal alterations of TOP2A, its interacting proteins, and its modifications may have a critical role in CIN in human cancers. Clinically, a large arsenal of topoisomerase inhibitors has been used to suppress DNA replication in cancer. However, they often lead to the secondary development of leukemia because of their effect on the chromosomal decatenation checkpoint. Therefore, topoisomerase drugs must be used judiciously and administered on an individual basis. In this review, we highlight the biological function of TOP2A in chromosome segregation and the mechanisms that regulate this enzyme's expression and activity. We also review the roles of TOP2A and related proteins in human cancers, and raise a perspective for how to target TOP2A in personalized cancer therapy.


Assuntos
Antígenos de Neoplasias/fisiologia , Instabilidade Cromossômica , DNA Topoisomerases Tipo II/fisiologia , Proteínas de Ligação a DNA/fisiologia , Neoplasias/tratamento farmacológico , Medicina de Precisão/métodos , Animais , Segregação de Cromossomos/genética , Proteínas de Ligação a DNA/antagonistas & inibidores , Progressão da Doença , Humanos , Neoplasias/genética , Proteínas de Ligação a Poli-ADP-Ribose , Inibidores da Topoisomerase II/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA